Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509044-96-00

Enrollment

Registered

2024-05-21

Start date

2018-12-21

Completion date

Unknown

Last updated

2024-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectabel gastric and gastroesophageal junction adenocarcinoma

Brief summary

Histopathological response rate within 30 days post surgery

Detailed description

Microscopically radical resection rate: Within 30 Days post surgery, Treatment completion rate: After completion of neoadjuvant and adjuvant chemotherapy., Disease free survival and overall survival: At follow up 12, 18, 24, 30, 36, 48 and 60 months from registration., Toxicity: Continuous during study treatment and then another 4 weeks, Complications: Within 30 days from surgery

Interventions

DRUGFLUOROURACIL

DRUGOXALIPLATIN

DRUGCALCIUM FOLINATE

DRUGIRINOTECAN HYDROCHLORIDE TRIHYDRATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Histopathological response rate within 30 days post surgery	—

Secondary

Measure	Time frame
Microscopically radical resection rate: Within 30 Days post surgery, Treatment completion rate: After completion of neoadjuvant and adjuvant chemotherapy., Disease free survival and overall survival: At follow up 12, 18, 24, 30, 36, 48 and 60 months from registration., Toxicity: Continuous during study treatment and then another 4 weeks, Complications: Within 30 days from surgery	—

Countries

Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026